Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veliparib and RAD51 Assay in Advanced Cancer
NCT03044795Phase 2Withdrawn
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2019
- Primary completion
- Nov 2020
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of veliparib in triple-negative breast cancer (TNBC), ovarian cancer, breast cancer, head and neck cancer (HNC), non-small cell lung cancer (NSCLC), sponsored by University Medical Center Groningen. Planned start Nov 2019; status: withdrawn.
02
Drugs
veliparib
03
Conditions
triple-negative breast cancer (TNBC)ovarian cancerbreast cancerhead and neck cancer (HNC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03044795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03044795.